Hepion Pharmaceuticals (HEPA)
(Delayed Data from NSDQ)
$0.76 USD
-0.06 (-7.20%)
Updated Aug 23, 2024 03:54 PM ET
After-Market: $0.74 -0.02 (-2.63%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.76 USD
-0.06 (-7.20%)
Updated Aug 23, 2024 03:54 PM ET
After-Market: $0.74 -0.02 (-2.63%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Wall Street Analysts Think Hepion Pharmaceuticals, Inc. (HEPA) Could Surge 674.09%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 674.1% upside potential for Hepion Pharmaceuticals, Inc. (HEPA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days
by Zacks Equity Research
Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.
Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Hepion Pharmaceuticals, Inc. (HEPA) and ICU Medical (ICUI) have performed compared to their sector so far this year.
Has Hepion Pharmaceuticals, Inc. (HEPA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Hepion Pharmaceuticals, Inc. (HEPA) and BioDelivery Sciences International (BDSI) have performed compared to their sector so far this year.
Hepion Pharmaceuticals (HEPA) Jumps: Stock Rises 9%
by Zacks Equity Research
Hepion Pharmaceuticals (HEPA) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Hepion (HEPA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Hepion (HEPA) stock based on the movements in the options market lately.
Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data
by Zacks Equity Research
It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.
Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII
by Zacks Equity Research
Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII
5 Stocks in Focus as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF
by Zacks Equity Research
Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF
Buy These 5 Stocks as New Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Healthcare ETFs Win in October: Here's Why
by Sweta Killa
The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.
Biotech ETFs Surge on a Flurry of Positive News
by Sweta Killa
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.